Therefore, targeting Bcl-2 may provide a potential therapeutic strategy for angiogenesis, and investigation of more effective Bcl-2-based anti-angiogenic agents may offer potential novel breast cancer therapy. This evidence concerns the gene BCL2 and breast cancer.